We work on drug discovery by combining our proprietary global top level antibody engineering and cyclic peptide technology and biological hypothesis of disease causing mechanism to solve the unmet medical needs.

T-Cell Redirecting Antibody

T-Cell Redirecting Antibody is a bispecific antibody for cancer immunotherapy, which binds to tumor antigen and CD3 expressed on the T cell to redirect T cells to potently kill tumor antigen expressing cancer cells. Our first T-Cell Redirecting Antibody, ERY974, is now being tested in clinical study, and we have multiple T-Cell Redirecting Antibody projects in the drug discovery stage.

Reference Article:

An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors

Sci Transl Med. 2017 Oct 4;9(410):eaal4291.

< Back